Results 161 to 170 of about 17,579 (227)

Detection of viruses in clinical samples by use of metagenomic sequencing and targeted sequence capture [PDF]

, 2018
Buller, Richard, Cannella, Maria T, Herter, Brandi, Storch, Gregory A, Wylie, Kristine M, Wylie, Todd N   +5 more
core   +1 more source

AlphaFold Prediction of Protein-Protein Interactions in the <i>Flaviviridae</i> Proteomes. [PDF]

Int J Mol Sci
Surya W, Goh J, Ponniah C, Torres J.
europepmc   +1 more source

Development of a Norway Rat Hepacivirus Reporter for High-Throughput Quantification of Neutralising Antibodies

Kennedy MJ, Wolfisberg R, Thorselius CE, Collignon L, Lundsgaard EA, Nielsen L, Holmbeck K, Bukh J, Scheel TKH.   +8 more
europepmc   +1 more source

Characteristics of a Chinese Cohort of Patients with Chronic Hepatitis C Infection (2019-2023) and a Case Report of Resistance-associated Substitutions to Sofosbuvir-velpatasvir Treatment. [PDF]

J Clin Transl Hepatol
Xiong H, Pan S, Zhou C, Shi H, Xie Y, Guo J.   +5 more
europepmc   +1 more source

Strategies of Classical Swine Fever Immune Evasion. [PDF]

Int J Mol Sci
Zhang Y, Li F, Liu Y.
europepmc   +1 more source

Structural bioinformatics approaches for predicting novel drug targets in hepatitis C virus proteins: a comprehensive analysis. [PDF]

Sci Rep
Qu M, Gao M, Sang X, Yu M, Guan Z, Chang W.   +5 more
europepmc   +1 more source

Reinfection and Resistance Associated Substitutions Following a Minimal Monitoring Approach for Hepatitis C Virus Treatment in MINMON Trial. [PDF]

Clin Infect Dis
Han WM, Solomon SS, Smeaton L, Avihingsanon A, Wagner Cardoso S, Li J, Parvangada A, Sulkowski M, Naggie S, Martin R, Mo H, Maiorova E, Wyles D.   +12 more
europepmc   +1 more source

Mechanisms and Therapeutic Strategies for HCV/HBV-Associated B-Cell Non-Hodgkin's Lymphomas: A Viewpoint. [PDF]

Oncol Res
Carloni G, Rinaldi M.
europepmc   +1 more source

Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks. [PDF]

J Virol
Fedorchenko SV, Klimenko Z, Martynovich T, Solianyk I, Suprunenko T.   +4 more
europepmc   +1 more source